Published in Br J Cancer on May 19, 2003
Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell Death Dis (2011) 1.28
Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem (2006) 1.22
Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res (2006) 1.21
Targeting caspases in cancer therapeutics. Biol Chem (2013) 1.13
Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A. Oncotarget (2014) 1.12
Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Br J Pharmacol (2006) 1.04
Inflammatory Mechanisms Associated with Prostatic Inflammation and Lower Urinary Tract Symptoms. Curr Prostate Rep (2008) 1.02
Functional role of KLF10 in multiple disease processes. Biofactors (2010) 1.01
Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene (2005) 0.91
Retracted Observational study: daily treatment with a new compound "Tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms. BMC Surg (2012) 0.90
The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression. Oncotarget (2014) 0.89
The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother (2004) 0.88
Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle. Neoplasia (2007) 0.86
Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res (2007) 0.85
Advances in the design and synthesis of prazosin derivatives over the last ten years. Expert Opin Ther Targets (2011) 0.84
Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport. PLoS One (2012) 0.79
Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder. Urology (2005) 0.78
The antihypertension drug doxazosin suppresses JAK/STATs phosphorylation and enhances the effects of IFN-α/γ-induced apoptosis. Genes Cancer (2014) 0.77
Mining for Candidate Genes Related to Pancreatic Cancer Using Protein-Protein Interactions and a Shortest Path Approach. Biomed Res Int (2015) 0.77
Terazosin treatment induces caspase-3 expression in the rat ventral prostate. J Clin Med Res (2013) 0.76
Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer. World J Surg Oncol (2017) 0.75
Discovery of Fluorescence Polarization Probe for the ELISA-Based Antagonist Screening of α1-Adrenergic Receptors. ACS Med Chem Lett (2016) 0.75
Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia. Int J Mol Sci (2016) 0.75
The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers. Int J Mol Sci (2016) 0.75
Label-Free Dynamic Mass Redistribution Reveals Low-Density, Prosurvival α1B-Adrenergic Receptors in Human SW480 Colon Carcinoma Cells. J Pharmacol Exp Ther (2017) 0.75
Insights into cardio-oncology: Polypharmacology of quinazoline-based α1-adrenoceptor antagonists. World J Cardiol (2015) 0.75
Phosphatidylinositol 3-Kinase/AKT Pathway Inhibition by Doxazosin Promotes Glioblastoma Cells Death, Upregulation of p53 and Triggers Low Neurotoxicity. PLoS One (2016) 0.75
Transforming growth factor-beta type I receptor/ALK5 contributes to doxazosin-induced apoptosis in H9C2 cells. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.75
A novel quinazolinone derivative induces cytochrome c interdependent apoptosis and autophagy in human leukemia MOLT-4 cells. Toxicol Rep (2014) 0.75
The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol (1996) 22.30
TGFbeta signaling in growth control, cancer, and heritable disorders. Cell (2000) 12.38
Cancer statistics, 2000. CA Cancer J Clin (2000) 12.32
Caspases: the executioners of apoptosis. Biochem J (1997) 11.99
How cells read TGF-beta signals. Nat Rev Mol Cell Biol (2000) 8.93
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med (1989) 7.01
The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell (1997) 6.34
Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst (2000) 3.63
Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA (1993) 3.46
Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest (2001) 3.40
Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev (1997) 3.33
TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity (2001) 3.20
Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene (2001) 2.71
The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci (2002) 1.90
Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate (2002) 1.86
Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol (1989) 1.82
Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor beta. J Biol Chem (2000) 1.71
Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells. J Natl Cancer Inst (1999) 1.69
Overexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells. J Clin Invest (1997) 1.67
Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene (1999) 1.62
Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res (2000) 1.48
The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci U S A (2001) 1.44
Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem (1997) 1.38
Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res (2000) 1.29
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Res (2002) 1.26
Smad7 inhibits the survival nuclear factor kappaB and potentiates apoptosis in epithelial cells. Oncogene (2001) 1.24
Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res (2000) 1.23
DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res (1996) 1.22
Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Res (1999) 1.18
A zinc-finger transcription factor induced by TGF-beta promotes apoptotic cell death in epithelial Mv1Lu cells. FEBS Lett (1999) 1.17
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol (1999) 1.16
Oncogenic ras represses transforming growth factor-beta /Smad signaling by degrading tumor suppressor Smad4. J Biol Chem (2001) 1.15
Role of androgens in prostatic cancer. Vitam Horm (1994) 1.14
Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol (1988) 1.13
Evidence for a role of the JNK cascade in Smad7-mediated apoptosis. J Biol Chem (2001) 1.12
Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. J Urol (2003) 1.08
Bcl-xL blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. J Biol Chem (2001) 1.04
Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis (2002) 0.99
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate (2001) 0.95
Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate (2001) 0.93
Cytokine-specific induction of the TGF-beta inducible early gene (TIEG): regulation by specific members of the TGF-beta family. J Cell Biochem (2000) 0.92
Signal transduction. Feedback from inhibitory SMADs. Nature (1997) 0.85
Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension. Drugs (1988) 0.84
Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy. Urology (1988) 0.83
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Caspase control: protagonists of cancer cell apoptosis. Exp Oncol (2012) 1.69
Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus. Proc Natl Acad Sci U S A (1991) 1.63
Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res (1997) 1.44
Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res (2001) 1.35
Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol (1996) 1.30
bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology (1998) 1.29
Collagen-induced morphogenesis and expression of the alpha 2-integrin subunit is inhibited in c-erbB2-transfected human mammary epithelial cells. Oncogene (1993) 1.29
Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl (1993) 1.28
Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res (2000) 1.23
Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ (1998) 1.22
Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res (1999) 1.18
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol (1999) 1.16
Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression. Int J Cancer (1996) 1.12
Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Res (1991) 1.12
Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate (1989) 1.11
Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology (1990) 1.07
Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol (1999) 1.04
Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer (1997) 1.04
Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis (2002) 0.99
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate (2001) 0.95
Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate (2001) 0.93
Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review). Oncol Rep (2000) 0.92
Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology (2001) 0.92
Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol (2001) 0.92
Racial differences in prostate cancer growth: apoptosis and cell proliferation in Caucasian and African-American patients. Prostate (2000) 0.89
Human immunodeficiency virus-1 Tat protein up-regulates interleukin-6 and interleukin-8 expression in human breast cancer cells. Inflamm Res (2005) 0.87
Effect of estrogen withdrawal on nitric oxide synthase expression and apoptosis in the rat vagina. Urology (1998) 0.86
Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT. Oncogene (2008) 0.86
Genetic instability and the acquisition of metastatic ability by rat mammary cancer cells following v-H-ras oncogene transfection. Cancer Res (1990) 0.85
Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention. Prostate Cancer Prostatic Dis (2005) 0.83
Biological basis for chemohormonal therapy for prostatic cancer. Cancer Treat Res (1989) 0.81
Future concepts in the medical therapy of benign prostatic hyperplasia. Curr Opin Urol (2001) 0.81
Biological significance of measurable androgen levels in the rat ventral prostate following castration. Prostate (1987) 0.80
Transfection of a murine fibrosarcoma with intercellular adhesion molecule-1 enhances the response to adoptive immunotherapy. Surgery (1995) 0.80
Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene. Prostate (1994) 0.79
Rare incidence of human papillomavirus types 16 and 18 in primary and metastatic human prostate cancer. Urology (1994) 0.79
Enhanced expression of ICAM-1 in a murine fibrosarcoma reduces tumor growth rate. J Surg Res (1995) 0.79
The role of tumor-associated antigens in the biology and immunotherapy of breast cancer. Ann N Y Acad Sci (1993) 0.77
Intranuclear distribution of androgen receptors in human prostate carcinoma. J Endocrinol (1987) 0.76
Collagen VII expression in human chronic wounds and scars. J Pathol (1997) 0.76
Association states of androgen receptors in nuclei of human benign hypertrophic prostate. Prostate (1986) 0.76
Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer. Urol Res (1987) 0.75
Evaluation of biopsy techniques for androgen receptor assay in human prostatic tissue. Br J Urol (1986) 0.75
Reversion of human prostate tumorigenic growth by azatyrosine. Urology (1995) 0.75
Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diaziridinyl-4,9-diazadodecane, results in therapeutic efficacy and enhanced radiosensitivity of human prostate cancer. Cancer Res (1998) 0.75
Potent in vitro anticancer activities of ring-expanded ("fat") nucleosides containing the imidazo[4,5-e][1,3]diazepine ring system. Nucleosides Nucleotides Nucleic Acids (2001) 0.75
Human hepatocellular carcinoma tumor xenografts. Their androgen-receptor status and growth responses to castration. Dig Dis Sci (1988) 0.75
New approaches to the evaluation of the metastatic ability of renal cancer and new approaches to chemotherapy. Eur Urol (1990) 0.75
Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. J Urol (1993) 0.75